Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Flamel Technologies has entered a multi-year supply agreement with GlaxoSmithKline (GSK) for the production of Coreg CR microparticles.
Subscribe to our email newsletter
As per the agreement, Flamel Technologies will supply Coreg CR microparticles for GSK over a period of many years for assured minimum payments.
Flamel CEO Stephen H Willard said the new supply agreement would provide the company and its shareholders with higher margins and greater certainty.
"We believe that this agreement further strengthens our ability to develop both of our best-in-class drug delivery platforms," Willard added.